NOVACAP
Acquired by
ARDIAN
NOVACAP acquired by ARDIAN
Target
NOVACAP
Acquirer
ARDIAN
Context
Ardian (then AXA Private Equity) entered into a definitive agreement to acquire a majority stake in Novacap from the private equity firm Bain Capital. The transaction marked the second major LBO for the chemical group since its carve-out from Rhodia in 2003. The strategic rationale for Ardian centered on transforming a primarily French-centric industrial producer into a global specialty chemical platform. The investment plan focused on two main pillars: accelerating international expansion and diversifying the product mix toward high-growth pharmaceutical and health markets. This transition aimed to reduce the group's exposure to cyclical commodity chemicals in favor of more stable, high-margin specialty ingredients.
NOVACAP, which reported an EBITDA margin of LOGIN in 2010, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN discount to the 8.7x average currently observed in the Industry & Manufacturing sector.
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Industry & Manufacturing market trends
Target
Novacap is an international specialty chemicals group headquartered in Lyon, France, specializing in the production and distribution of essential chemical ingredients. The organization is a global leader across diversified end-markets, including pharmaceuticals, healthcare, cosmetics, fragrances, food, animal nutrition, and environmental services. Its extensive product portfolio includes active pharmaceutical ingredients (APIs) such as aspirin and paracetamol, as well as salicylic acid, soda ash, sodium bicarbonate, and oxygenated solvents. The business model transitioned from a France-centric operation to a global platform with 14 production facilities worldwide and a workforce of 1,600 people, half of whom are based in Asia. Organized into three divisions—Mineral Specialties, Pharmaceutical & Cosmetics, and Performance Chemicals—the group serves over 750 clients globally, emphasizing sustainable development and high-value chemical synthesis for mission-critical consumer products.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with NOVACAP
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 04/2016 | EURAZEO / MERIEUX EQUITY PARTNERS | NOVACAP | FRANCE | Specialty Chemicals | Eurazeo and Mérieux Développement have signed an agreement to acquire a majority stake in Novacap from Ardian, which had held the company since March 2011. Ardian will retain a minority stake to maintain its commitment to the management team led by Pierre Luzeau. During Ardian's five-year ownership, Novacap underwent a massive transformation, executing six external acquisitions (notably in China and Germany) totaling approximately €240 million. This was complemented by an €85 million organic investment program to upgrade production tools. The strategic rationale for the new owners is to capitalize on Novacap’s reinforced position in high-margin target markets (pharmacy, health, and cosmetics), which now represent 68% of the group's activity compared to 44% previously. The transaction highlights Novacap's shift into a truly global player, with a strong footprint in Asia and a diversified revenue stream across essential chemical sectors. The new partnership aims to leverage Eurazeo’s financial strength and Mérieux’s healthcare network to pursue further international growth and solidify the group’s leadership in the specialty ingredients market. |
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.